Alnylam Pharmaceuticals (NASDAQ: ALNY) plans to present clinical data on two pipeline drugs at the European Society of Cardiology Congress 2026 in Munich, Germany, from August 28 to 31.
The company will highlight results from the HELIOS-B Phase 3 study evaluating vutrisiran (AMVUTTRA) in patients receiving background stabilizer therapy. The findings are scheduled for the Late-Breaking Science session on August 30. Additional analyses will address healthy aging, functional capacity, safety, and treatment outcomes by sex. A separate real-world analysis, Amylo’ExTTRa, will examine the multisystem burden of transthyretin amyloidosis with cardiomyopathy (ATTR-CM) beyond cardiac symptoms, using data from the French National Health Data System.
Alnylam will also present subgroup data from the KARDIA-3 Phase 2 study evaluating zilebesiran, an investigational hypertension treatment, in combination with a diuretic for patients with uncontrolled high blood pressure. The ZENITH Phase 3 cardiovascular outcomes trial, co-developed with Roche, will be discussed as well.
AMVUTTRA, administered quarterly via subcutaneous injection, is approved in the EU for treating hereditary transthyretin amyloidosis in adults with stage 1 or 2 polyneuropathy and for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy. Zilebesiran remains in clinical development for hypertension management.
Transthyretin amyloidosis, caused by the accumulation of pathogenic transthyretin proteins as amyloid deposits, affects an estimated more than 500,000 people globally, with approximately 80% of cases undiagnosed, according to Alnylam.
